Nanobac Pharmaceuticals Incorporated Stock Number Of Shares Shorted
| NNBP Stock | USD 0.0001 0.00 0.000003% |
Nanobac Pharmaceuticals Incorporated fundamentals help investors to digest information that contributes to Nanobac Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Nanobac Stock. The fundamental analysis module provides a way to measure Nanobac Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nanobac Pharmaceuticals stock.
Nanobac | Number Of Shares Shorted |
Nanobac Pharmaceuticals Incorporated Company Number Of Shares Shorted Analysis
Nanobac Pharmaceuticals' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Nanobac Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Nanobac Pharmaceuticals is extremely important. It helps to project a fair market value of Nanobac Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Nanobac Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nanobac Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nanobac Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Nanobac Pharmaceuticals Incorporated has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 100.0% higher than that of the company.
Nanobac Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nanobac Pharmaceuticals' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nanobac Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Nanobac Pharmaceuticals by comparing valuation metrics of similar companies.Nanobac Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
Nanobac Fundamentals
| Return On Asset | -0.37 | ||||
| Operating Margin | (151.42) % | ||||
| Current Valuation | 124.75 K | ||||
| Price To Earning | (0.02) X | ||||
| Price To Sales | 7.08 X | ||||
| Revenue | 17.62 K | ||||
| Gross Profit | 3.1 K | ||||
| EBITDA | (3.97 M) | ||||
| Net Income | (6.58 M) | ||||
| Cash And Equivalents | 3.93 K | ||||
| Total Debt | 4.12 M | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (910.89 K) | ||||
| Beta | -38.01 | ||||
| Market Capitalization | 124.75 K | ||||
| Total Asset | 7.22 M | ||||
| Retained Earnings | (28.93 M) | ||||
| Working Capital | (6.71 M) | ||||
| Current Asset | 31 K | ||||
| Current Liabilities | 6.75 M | ||||
| Net Asset | 7.22 M |
About Nanobac Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nanobac Pharmaceuticals Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nanobac Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nanobac Pharmaceuticals Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.